Elicera Therapeutics, a cell and gene therapy company developing immuno-oncology treatments with a focus on CAR T-cells and oncolytic viruses, has appointed Karin Hoogendoorn (PharmD) to the Board.
She joins the Gothenburg, Sweden headquartered company as a key cell therapy expert. The company is working on accelerated development of its next generation oncolytic virus and CAR T-cell clinical and pre-clinical programs, together with its proprietary iTANK platform for optimizing CAR T-cells.
Hoogendoon has 25 years of experience in the pharmaceutical industry, predominantly in the field of advanced therapy medicinal products (ATMPs), monoclonal antibodies and viral vector based vaccines. She has held various roles of increasing responsibility covering chemical, manufacturing and controls (CMC) and regulatory affairs from pre-clinical to commercial phases for small, medium and large pharmaceutical companies in the Netherlands, Switzerland, Sweden and Japan.
She is currently a member of the International Advisory Board of the Swedish Centre for Advanced Medical Products (CAMP).